SCHEMBL5578061

SCHEMBL5578061

CCOC(=O)Nc1nc2[nH]nc(-n3cncc3-c3ccccc3Cl)c2s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 3/20 0.43
ALDH1A1 P00352 6/20 0.41
HSD17B10 Q99714 5/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2C9 P11712 1/20 0.41
KDM4E B2RXH2 4/20 0.40
HPGD P15428 4/20 0.40
ADORA3 P0DMS8 3/20 0.40
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HTT P42858 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ADORA2B P29275 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
CASP3 P42574 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14473082 0.88 SMN1; SMN2 (0.41) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL5577957 0.87 LIMK1 (0.44) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL14454995 0.86 ALDH1A1 (0.43) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL14455001 0.86 GSK3B (0.46) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL5577933 0.85 PAK1 (0.35) SMN1; SMN2NPC1ALDH1A1HSD17B10CYP2C19
SCHEMBL14455022 0.84 GPBAR1 (0.34) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL14455002 0.84 LIMK1 (0.47) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL14454855 0.83 MEN1 (0.45) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL14455025 0.82 PIK3CG (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1HPGD
SCHEMBL5577958 0.82 GPBAR1 (0.38) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators SGX PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
WO-2007059341-A2 PYRAZOLOTHIAZOLE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173488-A1 Pyrazolothiazole Protein Kinase Modulators MAP4K2, MAP4K5, MAP4K3 SMN1; SMN2 3826/4885RAB9A 1840/4885NPC1 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.